<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03939338</url>
  </required_header>
  <id_info>
    <org_study_id>BFH-Treg and CMR</org_study_id>
    <nct_id>NCT03939338</nct_id>
  </id_info>
  <brief_title>Combination With Treg Levels and CMR to Assess the Severity and Prognosis of Reperfusion Injury After PPCI in STEMI Patients</brief_title>
  <acronym>TregCMRRS</acronym>
  <official_title>Combination With Regulatory T Cell Levels and Cardiac Magnetic Resonance Imaging (CMR) to Assess the Severity and Prognosis of Reperfusion Injury After Primary PCI in STEMI Patients (TregCMRRS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine whether combination with regulatory T cell (Treg) levels and
      cardiac magnetic resonance imaging (CMR) are predictive of the severity of reperfusion injury
      following myocardial infarction and the prognosis in STEMI patients receiving primary
      percutaneous coronary intervention (PPCI).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MACE (major adverse cardiovascular events)</measure>
    <time_frame>12 months</time_frame>
    <description>nonfatal or fatal myocardial infarction, revascularization, cardiac death, nonfatal or fatal stroke, all cause of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse cardiac remodeling</measure>
    <time_frame>6 months</time_frame>
    <description>a cut-off value of 12% change in left ventricular end-diastolic volume between the acute and follow-up magnetic resonance scans</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <condition>Reperfusion Injury, Myocardial</condition>
  <arm_group>
    <arm_group_label>Participates</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treg levels and CMR results</intervention_name>
    <description>This is an observational study. Exposure: Different Treg levels and CMR results.</description>
    <arm_group_label>Participates</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to Beijing Friendship Hospital,Capital Medical University with a
        confirmed STEMI diagnosis undergoing primary percutaneous coronary intervention
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed STEMI diagnosis

          -  Undergoing primary percutaneous coronary intervention (presenting &lt;12 hours after
             symptom onset)

          -  Patients were able to complete cardiac magnetic resonance imaging (CMR) and speckle
             tracking imaging echocardiogram (STE) examinations

          -  Patients agreed and provided informed consent

        Exclusion Criteria:

          -  Previous myocardial infarction or revascularization (PCI or CABG)

          -  Congestive heart failure with LVEF&lt;40%

          -  Atrial fibrillation

          -  Renal insufficiency (GFR &lt; 30 ml/min/1.73m^2)

          -  Acute infectious diseases within nearly 3 months

          -  Rheumatic immune system diseases

          -  Malignant tumors

          -  Claustrophobia

          -  Contraindicated to CMR

          -  Patients do not agree to be included in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongwei Li, M.D.</last_name>
    <phone>0086 10 63139780</phone>
    <email>lhw19656@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bing Hua, M.D.</last_name>
      <phone>0086 10 63139795</phone>
      <email>HuaBing199008@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>June 25, 2019</last_update_submitted>
  <last_update_submitted_qc>June 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Hongwei Li, MD</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Myocardial Reperfusion Injury</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

